We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+8.03%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$307M
AUM Growth
-$36.3M
Cap. Flow
+$1.28M
Cap. Flow %
0.42%
Top 10 Hldgs %
92.15%
Holding
24
New
2
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
NNOX icon
Nano X Imaging
NNOX
+$929K
2
APLM icon
Apollomics
APLM
+$356K
3
VTGN icon
VistaGen Therapeutics
VTGN
+$33.3K

Top Sells

Rank Stock Value
1
CALC icon
CalciMedica
CALC
+$25K
2
GYRE icon
Gyre Therapeutics
GYRE
+$17K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
1
Legend Biotech
LEGN
$3.93B
$78.6M 25.55%
1,629,173
– –
PTGX icon
2
Protagonist Therapeutics
PTGX
$9.8B
$56.3M 18.32%
2,449,183
– –
MGTX icon
3
MeiraGTx Holdings
MGTX
$1.17B
$34.3M 11.17%
6,641,064
– –
CVRX icon
4
CVRx
CVRX
$78.3M
$32.6M 10.6%
3,495,575
– –
XNCR icon
5
Xencor
XNCR
$1.71B
$20.9M 6.79%
748,062
– –
FATE icon
6
Fate Therapeutics
FATE
$294M
$19.3M 6.27%
3,379,064
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$13.8M 4.5%
3,670,516
– –
PRCT icon
8
Procept Biorobotics
PRCT
$1.26B
$10.2M 3.31%
357,939
– –
HLTH
9
DELISTED
Cue Health Inc. Common Stock
HLTH
$10.1M 3.29%
5,548,864
– –
PNT
10
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$7.27M 2.36%
1,000,000
– –
ARWR icon
11
Arrowhead Research
ARWR
$12.1B
$6.29M 2.05%
247,598
– –
VOR icon
12
Vor Biopharma
VOR
$1.38B
$5.78M 1.88%
53,733
– –
ACET icon
13
Adicet Bio
ACET
$77.3M
$4.2M 1.37%
45,559
– –
ALDX icon
14
Aldeyra Therapeutics
ALDX
$86.9M
$3.92M 1.28%
394,834
– –
NNOX icon
15
Nano X Imaging
NNOX
$73.2M
$1.83M 0.6%
317,704
+121,476
+62% +$929K
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$717K 0.23%
281,052
– –
PHGE icon
17
BiomX
PHGE
$1.67M
$651K 0.21%
11,228
– –
APLM icon
18
Apollomics
APLM
$38.1M
$321K 0.1%
+133
New +$356K
CLSD
19
DELISTED
Clearside Biomedical
CLSD
$176K 0.06%
11,309
– –
TCON
20
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$159K 0.05%
4,200
– –
SENS icon
21
Senseonics Holdings Inc
SENS
$409M
$38.8K 0.01%
2,731
– –
VTGN icon
22
VistaGen Therapeutics
VTGN
$11.8M
$23.8K 0.01%
+6,350
New +$33.3K
GYRE icon
23
Gyre Therapeutics
GYRE
$693M
$13.9K ﹤0.01%
4,463
-4,464
-50% -$17K
CALC icon
24
CalciMedica
CALC
$20.2M
– –
-3,539
Closed -$25K

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q1 2023 Portfolio in Review

As of Q1 2023, Johnson & Johnson held 24 positions worth $307M, down 11% from $344M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Johnson & Johnson's Q1 2023 filing shows 2 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was Apollomics: 133 shares worth $321K. The largest sale was CalciMedica, an estimated $25K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's largest Q1 2023 buy was Apollomics: 133 shares worth $321K.
  • Johnson & Johnson added most to Nano X Imaging in Q1 2023, an estimated $929K increase.
  • Johnson & Johnson's biggest Q1 2023 reduction was Gyre Therapeutics, cutting an estimated $17K.
  • Johnson & Johnson fully exited CalciMedica in Q1 2023, selling an estimated $25K.
  • Johnson & Johnson's ten largest holdings make up 92% of its $307M portfolio in Q1 2023.
  • Johnson & Johnson opened 2 new positions and closed 1 in Q1 2023.
  • Johnson & Johnson's portfolio value fell 11% quarter-over-quarter to $307M.

Based on Johnson & Johnson's 13F filing for Q1 2023, filed 11 May 2023.